New developments in topical sequential therapy for psoriasis.
Topical agents for the treatment of psoriasis are indicated for patients whose affected area is less then 10% of their skin. However, for long-term use, their effectiveness can be limited. Topical sequential therapy involves the application of a class I corticosteroid and calcipotriene in three different phases: the clearance phase, the transition phase and the maintenance phase. It is an accepted and widely practiced technique that provides a balance between maximizing efficacy and minimizing side-effects thus offering patients rapid clearance of their psoriatic lesions and long-term maintenance of remission.
Koo
J Y M
JY
Department of Dermatology, School of Medicine, University of California at San Francisco, San Francisco, CA, USA.
D000287:Administration, Topical; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D002117:Calcitriol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D011565:Psoriasis / Q000188:drug therapy*
D000305:Adrenal Cortex Hormones; D003879:Dermatologic Agents; C055085:calcipotriene; D002117:Calcitriol